Prudence Edwards is a Data Engineer in the Global MSAT Process Analytics team, at Thermo Fisher Scientific (Patheon), based at their Biologics site in Brisbane, Australia. Prudence graduated with a degree in Chemical and Bioprocess Engineering from The University of Queensland, Australia, with a dual degree in Engineering from Centrale Marseille, France (BE (Hons)/ME//diplôme d’ingénieur). She was the leader of the winning team for the 2021 Student and Emerging Leader Hackathon, and was actively involved in formulating the solution. Since the hackathon, Prudence has continued to be a frequent participant at ISPE events and meetings, serving on the Organising Committee at the 2022 and 2023 Biotechnology Conference. Prudence has a particular interest in digitalisation in the biopharmaceutical industry, having completed an internship working on initiatives to digitalize legacy testing methods at Sanofi Vaccines in their Quality Control Centre of Excellence. Prudence's current role includes supporting Thermo Fisher with data analysis and visualisation, and implementing digital systems on site.
Digital transformation isn’t a future concept in the biopharmaceutical industry—it is already impacting manufacturing and quality control processes. Recent advancements and best practices will be showcased at the upcoming 2025 ISPE Biotechnology Conference, where the track “Implementing Digital Initiatives in the Biopharmaceutical Industry: Where Are We on the Road Map?” dives deep into the...
To meet the biopharmaceutical industry’s duty to manufacture safe and effective therapies for patients, a robust quality system is fundamental to success. A quality system should link to quality culture and prioritize focusing on quality, led by management, that fosters sustainable compliance and consistent production of high-quality drugs. Strong quality culture attributes include a proactive...
The advantages that come with a fully digitalized plant for manufacturing biopharmaceuticals are well documented and showcased throughout the biopharmaceutical industry and will be a featured topic during the 2023...
It goes without saying that reflecting on the last few years, immense progress has been made in the biopharmaceutical industry. We have seen an industry prioritising collaboration and innovation, combined with a healthy competitive spirit, brought new technology to reality, and achieved milestones in twelve months that would previously have taken a decade.